Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse ...

In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab ...

The SMC has also has accepted Cladribine, also known as Mavenclad, for the treatment of relapsing-remitting multiple ...

The patients had all been treated with durvalumab/tremelimumab at Iwate Medical University in Japan between 2023 and 2024. The median age was 75.9 years and 86.4% were male. During the observation ...

Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard ...

Eight eligible patients were treated with upfront durvalumab and tremelimumab for two cycles. Patients then received NACT prior to breast surgery. Seven patients had baseline and interval breast ...

Tremelimumab has been accepted under priority review in the US for patients with unresectable liver cancer in combination with Imfinzi. AstraZeneca’s biologics license application (BLA) for ...

AstraZeneca's Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, supporting the indication of a single priming dose of the anti-CTLA4 antibody added ...

LONDON (dpa-AFX) - British drug major AstraZeneca Plc (AZN, AZN.L) Monday said its Biologics License Application or BLA for tremelimumab has been accepted for Priority Review in the United States.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, supporting the indication of a single ...